Stock Scorecard



Stock Summary for CRISPR Therapeutics AG (CRSP) - $38.04 as of 3/28/2025 2:44:29 PM EST

Total Score

7 out of 30

Safety Score

45 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for CRSP

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for CRSP

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for CRSP

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for CRSP

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for CRSP (45 out of 100)

Stock Price Rating (Max of 10) 8
Historical Stock Price Rating (Max of 10) 9
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 7
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 5
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for CRSP

Promising Genomics & Synthetic Biology Stocks to Consider in 2025 3/28/2025 1:39:00 PM
TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access 3/27/2025 11:00:00 AM
CRISPR Therapeutics AG ( CRSP ) Is a Trending Stock: Facts to Know Before Betting on It 3/25/2025 1:00:00 PM
CRISPR Therapeutics AG ( CRSP ) Surpasses Market Returns: Some Facts Worth Knowing 3/21/2025 9:50:00 PM
Cathie Wood Bets On Elon Musk's Tesla Despite Cybertruck Recall, Dumps Zuckerberg's Meta Shares Again - Meta Platforms ( NASDAQ:META ) , ARK Innovation ETF ( ARCA:ARKK ) 3/21/2025 1:29:00 AM
CRISPR Therapeutics AG ( CRSP ) Declines More Than Market: Some Information for Investors 3/20/2025 10:00:00 PM
Cathie Wood Offloads Meta Stock While Mark Zuckerberg Celebrates Llama AI Success - Meta Platforms ( NASDAQ:META ) , ARK Innovation ETF ( ARCA:ARKK ) 3/20/2025 1:22:00 AM
Cathie Wood Stands By Tesla's $2,600 Price Target Despite 40% Stock Drop: 'It's Winner Take Most - Coinbase Global ( NASDAQ:COIN ) , ARK Innovation ETF ( ARCA:ARKK ) 3/15/2025 1:00:00 PM
CRISPR Therapeutics AG ( CRSP ) is Attracting Investor Attention: Here is What You Should Know 3/14/2025 1:00:00 PM
Cathie Wood Hunts For Crypto Bargains Amid Bitcoin Decline, Ark Loads Up On Robinhood And Coinbase - ARK Innovation ETF ( ARCA:ARKK ) 3/14/2025 2:22:00 AM

Financial Details for CRSP

Company Overview

Ticker CRSP
Company Name CRISPR Therapeutics AG
Country USA
Description CRISPR Therapeutics AG, a gene editing company, focuses on the development of gene-based transformative drugs for serious human diseases. The company is headquartered in Zug, Switzerland.
Sector Name LIFE SCIENCES
Industry Name BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Most Recent Quarter 12/31/2024
Next Earnings Date 5/30/2025

Stock Price History

Last Day Price 38.04
Price 4 Years Ago 75.78
Last Day Price Updated 3/28/2025 2:44:29 PM EST
Last Day Volume 1,727,178
Average Daily Volume 2,188,757
52-Week High 68.39
52-Week Low 36.52
Last Price to 52 Week Low 4.16%

Valuation Measures

Trailing PE N/A
Industry PE 53.93
Sector PE 40.10
5-Year Average PE -11.54
Free Cash Flow Ratio 1.71
Industry Free Cash Flow Ratio 18.14
Sector Free Cash Flow Ratio 47.05
Current Ratio Most Recent Quarter 22.07
Total Cash Per Share 22.20
Book Value Per Share Most Recent Quarter 22.53
Price to Book Ratio 1.69
Industry Price to Book Ratio 11.03
Sector Price to Book Ratio 21.92
Price to Sales Ratio Twelve Trailing Months 87.44
Industry Price to Sales Ratio Twelve Trailing Months 59.91
Sector Price to Sales Ratio Twelve Trailing Months 27.78
Analyst Buy Ratings 12
Analyst Strong Buy Ratings 5

Share Statistics

Total Shares Outstanding 85,774,000
Market Capitalization 3,262,842,960
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -138.43%
Reported EPS 12 Trailing Months -4.34
Reported EPS Past Year -4.37
Reported EPS Prior Year -1.96
Net Income Twelve Trailing Months -366,252,000
Net Income Past Year -366,252,000
Net Income Prior Year -153,610,000
Quarterly Revenue Growth YOY -82.30%
5-Year Revenue Growth -33.42%
Operating Margin Twelve Trailing Months -181.00%

Balance Sheet

Total Cash Most Recent Quarter 1,903,826,000
Total Cash Past Year 1,903,826,000
Total Cash Prior Year 1,693,692,000
Net Cash Position Most Recent Quarter 1,903,826,000
Net Cash Position Past Year 1,903,826,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 1,932,080,000
Total Stockholder Equity Prior Year 1,882,803,000
Total Stockholder Equity Most Recent Quarter 1,932,080,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -144,675,000
Free Cash Flow Per Share Twelve Trailing Months -1.69
Free Cash Flow Past Year -144,675,000
Free Cash Flow Prior Year -269,845,000

Options

Put/Call Ratio 0.33
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -1.13
MACD Signal -0.72
20-Day Bollinger Lower Band 35.49
20-Day Bollinger Middle Band 43.83
20-Day Bollinger Upper Band 52.16
Beta 1.76
RSI 36.71
50-Day SMA 49.20
150-Day SMA 55.44
200-Day SMA 64.51

System

Modified 3/28/2025 9:47:01 PM EST